First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J. Davis, Janice M. Mehnert, Sarah P. Blagden et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 93
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Charles W. Abbott et al.|Clinical Cancer Research|2025Cited by 1